SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Sparre M.)
 

Sökning: WFRF:(Sparre M.) > An open-label study...

  • Hesselstrand, RogerLund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Forskargruppen för systemisk skleros, Lund,Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund Systemic Sclerosis Research Group,Lund University Research Groups,Skåne University Hospital (författare)

An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod

  • Artikel/kapitelEngelska2021

Förlag, utgivningsår, omfång ...

  • 2021-07-31
  • Springer Science and Business Media LLC,2021

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:513d6a6b-0049-4091-a939-a08159db3870
  • https://lup.lub.lu.se/record/513d6a6b-0049-4091-a939-a08159db3870URI
  • https://doi.org/10.1186/s13075-021-02573-0DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Objectives: To evaluate the changes in disease-related biomarkers and safety of paquinimod, an oral immunomodulatory compound, in patients with systemic sclerosis (SSc). Methods: In this open-label, single-arm, multicenter study, SSc patients with a rapidly progressive disease received paquinimod for 8 weeks. Blood and skin biopsies were collected at baseline, during treatment, and at follow-up for the analyses of type I interferon (IFN) activity, chemokine (C-C motif) ligand 2 (CCL2), and the number of myofibroblasts. The safety of paquinimod was evaluated throughout the study. Results: Nine SSc patients were enrolled and completed the study treatment with paquinimod at 3 mg/day for 8 weeks. After the treatment, a reduction of type I IFN activity in the plasma from one patient with elevated baseline IFN activity was recorded. A trend towards reduced IFN activity in the skin after treatment was also observed in patients. The serum level of CCL2 was reduced in 7 of 9 patients after paquinimod treatment. There was a median reduction of 10% of the number of myofibroblasts in skin biopsies at week 8 compared to baseline. No change in modified Rodnan skin score and quality of life was detected in the study. Reported adverse events (AEs) were mild to moderate and expected with the most common being arthralgia (n = 3) and headache (n = 3), and C-reactive protein (CRP) increase. Conclusions: Analysis of biomarkers before and after treatment suggest reduced type I IFN activity and reduced number of myofibroblasts in lesional skin. Paquinimod was overall well tolerated with mild to moderate and expected AEs. Trial registration: ClinicalTrials.gov, NCT01487551. Registered on 7 September 2011.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Distler, Jörg H.W.Friedrich-Alexander University Erlangen-Nürnberg (författare)
  • Riemekasten, GabrielaUniversity Medical Center Schleswig-Holstein (författare)
  • Wuttge, Dirk M.Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Forskargruppen för systemisk skleros, Lund,Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund Systemic Sclerosis Research Group,Lund University Research Groups,Skåne University Hospital(Swepub:lu)reum-dwu (författare)
  • Törngren, MarieActive Biotech Research AB (författare)
  • Nyhlén, Helén C.Active Biotech Research AB (författare)
  • Andersson, FredrikActive Biotech Research AB (författare)
  • Eriksson, HelenaActive Biotech Research AB (författare)
  • Sparre, BirgittaActive Biotech Research AB (författare)
  • Tuvesson, HelénActive Biotech Research AB(Swepub:lu)tumo-htu (författare)
  • Distler, OliverUniversity Hospital of Zurich (författare)
  • Reumatologi och molekylär skelettbiologiSektion III (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Arthritis Research and Therapy: Springer Science and Business Media LLC23:11478-63541478-6362

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy